Effect of combination therapy with ribavirin and high-dose interferon-α2b for 24 weeks in chronic hepatitis C

Journal of Gastroenterology and Hepatology (Australia)

Volumn 21, Issue 1 PART2, 2006, Pages 308-312

  Abe, Shintaro ^a   Narita, Ryoichi ^a   Oto, Takeshi ^a   Tabaru, Akinari ^a   Otsuki, Makoto ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Chronic hepatitis C; Interferon 2b; Ribavirin; Sustained response

Indexed keywords

ALPHA2B INTERFERON; HEMOGLOBIN; RIBAVIRIN; VIRUS RNA;

ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GENOTYPE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; HYPERTHYROIDISM; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MENTAL CONCENTRATION; MENTAL DEFICIENCY; MYALGIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RIGOR; SERUM; SIDE EFFECT; TREATMENT OUTCOME;

EID: 33645319959     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04173.x     Document Type: Article

References (38)

1. Tsubota A Kumada H Chayama K et al. Relationship between pretreatment viremia level and response to interferon-α therapy in chronic hepatitis C differs in viral type 1 and 2 infections. Dig. Dis. Sci. 1996 41 1925 32.
2. Shiratori Y Kato N Yokosuka O et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group. Gastroenterology 1997 113 558 66.
3. Ferenci P Stauber R Propst A et al. Dose increase augments response rate to interferon-α in chronic hepatitis C. Dig. Dis. Sci. 1996 41 Suppl. 12 103 8.
4. Poynard T Leroy V Cohard M et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996 24 778 89.
5. Lindsay KL Davis GL Schiff ER et al. Response to higher doses of interferon α-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatitis Interventional Therapy Group. Hepatology 1996 24 1034 40.
6. Chemello L Bonetti P Cavalletto L et al. Randomized trial comparing three different regimens of α-2a-interferon in chronic hepatitis C. The TriVeneto Viral Hepatitis Group. Hepatology 1995 22 700 6.
7. Iino S. High dose interferon treatment in chronic hepatitis C. Gut 1993 34 Suppl. 2 114 18.
8. Canadian Association for the Study of the Liver. Canadian consensus conference on the management of viral hepatitis. Can. J. Gastroenterol. 2000 14 Suppl. B B5 20.
9. European Association for the Study of the Liver International Consensus Conference on Hepatitis C. Consensus statement. Paris, 26-28, February 1999. J. Hepatol. 1999 30 956 61.
10. Farrell GC. Consensus among consensus conferences on management of hepatitis C: what we knew then and are still sure about, what we are newly sure about, and what we still need to know. J. Gastroenterol. Hepatol. 2000 15 Suppl. E126 9.
11. McHutchison JG Gordon SC Schiff ER et al. Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 1998 339 1485 92.
12. Poynard T Marcellin P Lee SS et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998 352 1426 32.
13. Choo QL Richman KH Han JH et al. Genetic organization and diversity of the hepatitis C virus. Proc. Natl Acad. Sci. USA 1991 88 2451 5.
14. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994 20 15 20.
15. Bedossa P Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996 24 289 93.
16. Booth JC O'Grady J Neuberger J The Royal College of Physicians of London, The British Society of Gastroenterology. Clinical guidelines on the management of hepatitis C. Gut 2001 49 Suppl. 1 1 21.
17. Tsubota A Chayama K Arase Y et al. Factors useful in predicting the response to interferon therapy in chronic hepatitis C. J. Gastroenterol. Hepatol. 1993 8 535 9.
18. Tsubota A Chayama K Ikeda K et al. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 1994 19 1088 94.
19. Hino K Sainokami S Shimoda K et al. Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C. J. Med. Virol. 1994 42 299 305.
20. Lau JY Simmonds P Urdea MS. Implications of variations of 'conserved' regions of hepatitis C virus genome. Lancet 1995 346 425 6.
21. Poynard T Bedossa P Chevallier M et al. A comparison of three interferon α-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N. Engl. J. Med. 1995 332 1457 62.
22. Reichard O Foberg U Fryden A et al. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-α2b for 60 weeks. Hepatology 1994 19 280 5.
23. Saracco G Borghesio E Mesina P et al. Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon α-2b for chronic hepatitis type C. Results of a multicenter randomized trial. J. Hepatol. 1997 27 56 62.
24. Arase Y Ikeda K Tsubota A et al. Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load. J. Gastroenterol. 2003 38 158 63.
25. Reichard O Norkrans G Fryden A Braconier JH Sonnerborg A Weiland O. Randomized, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998 351 83 7.
26. Schalm SW Hansen BE Chemello L et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J. Hepatol. 1997 26 961 6.
27. Manns MP McHutchison JG Gordon SC et al. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 958 65.
28. Fried MW Shiffman ML Reddy KR et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002 347 975 82.
29. Hadziyannis SJ Sette H Morgan TR et al. PEGASYS International Study Group. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 2004 140 346 55.
30. Lai MY Kao JH Yang PM et al. Long-term efficacy of ribavirin plus interferon α in the treatment of chronic hepatitis C. Gastroenterology 1996 111 1307 12.
31. Abe S Narita R Hiura M Jia DM Tabaru A Otsuki M. Early decrease in serum IV-7S levels during IFN treatment predicts anti-fibrogenic effect in nonresponders with chronic hepatitis C. J. Gastroenterol. 2004 39 247 54.
32. Abe S Tabaru A Ono M et al. High-dose interferon-α therapy lowers the levels of serum fibrogenesis markers over 5 years in chronic hepatitis C. Hepatol. Res. 2003 25 22 31.
33. Abe S Kotoh K Arao S Tabaru A Otsuki M. Fas antigen expression on hepatocytes predicts the short- and long-term response to interferon therapy in patients with chronic hepatitis C. Scand. J. Gastroenterol. 2001 36 326 31.
34. Pol S Nalpas B Bourliere M et al. Combination of ribavirin and interferon-α surpasses high doses of interferon-α alone in patients with genotype-1b-related chronic hepatitis C. Hepatology 2000 31 1338 44.
35. Bekkering FC Stalgis C McHutchison JG Brouwer JT Perelson AS. Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model. Hepatology 2001 33 419 23.
36. Jessner W Gschwantler M Steindl-Munda P et al. Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study. Lancet 2001 358 1241 2.
37. Enomoto N Sakuma I Asahina Y et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N. Engl. J. Med. 1996 334 77 81.
38. Tsubota A Arase Y Suzuki F et al. High-dose interferon α-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load. J. Gastroenterol. 2004 39 155 61.